XML 115 R21.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Segment and Geographic Data | 12 Months Ended
--- | ---
Dec. 31, 2019
Segment Reporting [Abstract] |
Segment and Geographic Data | SEGMENT AND GEOGRAPHIC DATA We segregate our operations into three reportable business segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Corporate and Other category shown in the table below includes corporate and administration, corporate initiatives and share-based compensation, which includes compensation related to employee stock options, restricted stock units and performance stock unit grants and director stock options and restricted stock unit grants.
Segment Results |  |  |
| 2019 | 2018 | 2017
Orthopaedics | $ | 5,252 |  | $ | 4,991 |  | $ | 4,713 |
MedSurg | $ | 6,574 |  | 6,045 |  | 5,557 |
Neurotechnology & Spine | 3,058 |  | 2,565 |  | 2,174 |
Net sales | $ | 14,884 |  | $ | 13,601 |  | $ | 12,444 |
Orthopaedics | $ | 348 |  | $ | 350 |  | $ | 337 |
MedSurg | 379 |  | 285 |  | 315 |
Neurotechnology & Spine | 218 |  | 176 |  | 142 |
Segment depreciation and amortization | $ | 945 |  | $ | 811 |  | $ | 794 |
Corporate and Other | 99 |  | 155 |  | 65 |
Total depreciation and amortization | $ | 1,044 |  | $ | 966 |  | $ | 859 |
Orthopaedics | $ | 1,907 |  | $ | 1,804 |  | $ | 1,681 |
MedSurg | 1,635 |  | 1,444 |  | 1,228 |
Neurotechnology & Spine | 846 |  | 700 |  | 631 |
Segment operating income | $ | 4,388 |  | $ | 3,948 |  | $ | 3,540 |
Items not allocated to segments: |  |  |
Corporate and Other | $ | (480 | ) | $ | (431 | ) | $ | (402 | )
Acquisition and integration-related charges | (275 | ) | (123 | ) | (64 | )
Amortization of intangible assets | (464 | ) | (417 | ) | (371 | )
Restructuring related and other charges | (226 | ) | (220 | ) | (194 | )
Medical device regulations | (62 | ) | (12 | ) | — |
Recall-related matters | (192 | ) | (23 | ) | (173 | )
Regulatory and legal matters | 24 |  | (185 | ) | (39 | )
Consolidated operating income | $ | 2,713 |  | $ | 2,537 |  | $ | 2,297 |
Segment Assets and Capital Spending
Assets: | 2019 | 2018 | 2017
Orthopaedics | $ | 9,085 |  | $ | 8,873 |  | $ | 7,486 |
MedSurg | 12,066 |  | 10,417 |  | 9,759 |
Neurotechnology & Spine | 7,646 |  | 7,260 |  | 4,105 |
Total segment assets | $ | 28,797 |  | $ | 26,550 |  | $ | 21,350 |
Corporate and Other | 1,370 |  | 679 |  | 847 |
Total assets | $ | 30,167 |  | $ | 27,229 |  | $ | 22,197 |
Capital spending: |  |  |
Orthopaedics | $ | 125 |  | $ | 134 |  | $ | 138 |
MedSurg | 265 |  | 217 |  | 194 |
Neurotechnology & Spine | 29 |  | 31 |  | 50 |
Total segment capital spending | $ | 419 |  | $ | 382 |  | $ | 382 |
Corporate and Other | 230 |  | 190 |  | 216 |
Total capital spending | $ | 649 |  | $ | 572 |  | $ | 598 |
We measure the financial results of our reportable segments using an internal performance measure that excludes acquisition and integration-related charges, restructuring-related charges, reserves for certain product recall matters and reserves for certain legal and regulatory matters. Identifiable assets are those assets used exclusively in the operations of each business segment or allocated when used jointly. Corporate assets are principally cash and cash equivalents, marketable securities and property, plant and equipment. The countries in which we have local revenue generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); Europe, Middle East, Africa; Asia Pacific; and other foreign countries, which include Canada and countries in the Latin American region. Net sales are reported based off the geographic area of the Stryker location where the sales to the customer originated.
Geographic Information
| Net Sales |  | Net Property, Plant and Equipment
| 2019 | 2018 | 2017 |  | 2019 | 2018
United States | $ | 10,957 |  | $ | 9,848 |  | $ | 9,059 |  |  | $ | 1,561 |  | $ | 1,348 |
Europe, Middle East, Africa | 1,888 |  | 1,793 |  | 1,567 |  |  | 838 |  | 669 |
Asia Pacific | 1,617 |  | 1,532 |  | 1,413 |  |  | 95 |  | 96 |
Other countries | 422 |  | 428 |  | 405 |  |  | 73 |  | 178 |
Total | $ | 14,884 |  | $ | 13,601 |  | $ | 12,444 |  |  | $ | 2,567 |  | $ | 2,291 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration